New drug may shield cancer patients from dangerous infection risk
NCT ID NCT07434063
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This real-world study looks at whether a drug called mecapegfilgrastim can prevent neutropenia (a low white blood cell count) in cancer patients after chemotherapy, radiation, or immunotherapy. The study will follow 200 adults with solid tumors who are at high or moderate risk of developing neutropenia. Researchers will track how many patients get a fever with low white blood cells and how severe the neutropenia is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
mecapegfilgrastim injection (a drug to boost white blood cells)
What this could lead to
If successful, this could confirm that mecapegfilgrastim effectively prevents dangerous drops in white blood cells after cancer treatment, reducing infection risk.
What could go wrong
This is an observational study, not a controlled trial, so results may be less definitive. Side effects from the drug are possible, and it may not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUTROPENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
HebeiMuFH
RECRUITINGShijiazhuang, Hebei, China
Contact Phone: •••-•••-•••• Email: •••••@•••••